Dipiaron Overview
- Status
-
Private
- Latest Deal Type
-
Early Stage VC
- Investors
-
1
Dipiaron General Information
Description
Developer of an oral drug designed to help doctors treat type 2 diabetes mellitus, metabolic syndrome, and obesity. The company's drug is a GPR119 receptor agonist that stimulates the secretion of incretins and insulin, enabling type 2 diabetes patients to have an effective and safe treatment option that reduces the risk of complications.
Contact Information
Website
www.dipiaron.comCorporate Office
- Ter Skolkovo Innovation Center
- Bolshoy b-r, 42 p. 1
- Moscow, 121205
- Russia
Corporate Office
- Ter Skolkovo Innovation Center
- Bolshoy b-r, 42 p. 1
- Moscow, 121205
- Russia
Dipiaron Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Early Stage VC | 28-Sep-2022 | Completed | Clinical Trials - Phase 1 |
Dipiaron Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Unicorn Capital Partners | Venture Capital | Minority |
Dipiaron FAQs
-
Where is Dipiaron headquartered?
Dipiaron is headquartered in Moscow, Russia.
-
What industry is Dipiaron in?
Dipiaron’s primary industry is Drug Discovery.
-
Is Dipiaron a private or public company?
Dipiaron is a Private company.
-
What is Dipiaron’s current revenue?
The current revenue for Dipiaron is .
-
Who are Dipiaron’s investors?
Unicorn Capital Partners has invested in Dipiaron.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process